Welcome to our dedicated page for Cno Finl Group SEC filings (Ticker: CNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CNO Financial Group, Inc. (NYSE: CNO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a life and health insurer and financial services provider focused on middle-income America, CNO uses its filings to present detailed information on its insurance products, capital position and operating performance.
Investors can review CNO’s current reports on Form 8-K, which the company uses to furnish quarterly earnings press releases, quarterly financial supplements and additional financial and operating data. These filings commonly include metrics such as net income, net operating income, income from insurance products across annuity, health and life lines, fee income, investment income not allocated to product lines, and measures like book value per share and operating return on equity.
Over time, CNO’s SEC filings also provide insight into capital management and structure, including common stock dividends, share repurchase activity, reinsurance transactions with its wholly owned Bermuda reinsurance company, and technology modernization initiatives such as the TechMod project. Filings may describe changes in business mix, such as the decision to exit the fee services side of the Worksite Division to focus on core insurance offerings.
On Stock Titan, AI-generated highlights help explain the key points in lengthy documents, so users can quickly understand what each filing means for CNO’s insurance operations, investment portfolio and shareholders. Real-time updates from EDGAR ensure that new 8-Ks and other forms appear promptly, while tools for viewing insider-related information, capital actions and recurring reporting patterns make it easier to analyze CNO’s regulatory history.
BlackRock, Inc. filed Amendment No. 14 to Schedule 13G reporting beneficial ownership of 12,473,730 shares of CNO Financial Group common stock, representing 12.9% of the class as of the event date 09/30/2025.
BlackRock reports sole voting power over 12,106,902 shares and sole dispositive power over 12,473,730 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Various persons may have rights to dividends or sale proceeds through managed accounts, but no single person exceeds five percent of the outstanding common shares.
CNO Financial Group, Inc. furnished a Consumer Division Briefing investor presentation dated September 2025. The presentation is attached as Exhibit 99.1 and will also be posted in the Investors section of the company’s website at ir.CNOinc.com. The materials provide information on the company’s consumer division and are being furnished under the Securities Exchange Act of 1934 rather than filed, which affects how they are treated for liability purposes and whether they are incorporated into other SEC documents.
CNO Financial Group director Mary R. Henderson reported a sale of 6,300 shares of CNO common stock on 08/28/2025. The Form 4 shows the disposition was coded as a charitable donation and carried no cash proceeds (price $0). After the reported transaction, Ms. Henderson beneficially owned 73,460 shares in total, held directly.
The filing is a routine Section 16 disclosure by an insider and lists the transaction executor as Heidi M. Krings, Attorney-in-Fact, with a signature date of 08/29/2025. No options, derivatives, or other compensatory transactions are reported on this form.
Karen J. DeToro, President of the Worksite Division at CNO Financial Group (CNO), reported sales of common stock under a Rule 10b5-1 plan adopted May 6, 2025. The filing shows three separate dispositions on August 13-15, 2025 totaling 25,657 shares sold at weighted average prices of approximately $37.96, with reported per-trade weighted averages of $37.9588, $37.9788 and $37.8481. After these sales the reporting person beneficially owned 41,855 shares. The filing indicates the transactions were made pursuant to an affirmative-defense 10b5-1 plan and that detailed per-price breakdowns can be provided upon request.
CNO Financial Group insider filing (Form 4/A) shows that Karen J. DeToro, President of the Worksite Division and an officer of CNO (ticker: CNO), disposed of 1,417 shares of common stock on 01/02/2025. The shares were surrendered to the issuer to cover required tax withholding on vested restricted stock units, at an indicated price of $37.14 per share. Following the transaction, Ms. DeToro beneficially owned 58,918 shares. The filing is an amendment that corrects the amount disposed and the post-transaction beneficial ownership.
CNO Financial Group, Inc. (CNO) Form 144 reports a proposed sale of 9,228 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $349,262.27, based on an approximate sale date of 08/15/2025 on the NYSE. The filing lists total shares outstanding of 96,931,934. The securities were acquired as performance shares on 02/14/2023 (7,479 shares) and as restricted stock on 09/30/2021 (1,749 shares). The filer also reported recent sales: 6,509 shares on 08/14/2025 for $247,203.36 and 9,920 shares on 08/13/2025 for $376,551.30. The notice includes the standard representation regarding material nonpublic information and a broker identification.
Form 144 notice for proposed sale of CNO Financial Group, Inc. securities. The filing reports an intended sale of 3,457 common shares with an aggregate market value of $130,845.38. The shares represent part of outstanding common stock of 96,931,934 and the approximate proposed sale date is 08/15/2025 on the NYSE. The 3,457 shares were acquired from the issuer as restricted stock (1,985 shares, 03/25/2024) and performance shares (1,472 shares, 02/15/2024).
Recent sales by the same person are disclosed: Jeanne Linnenbringer sold a total of 11,282 common shares on 08/13/2025 and 08/14/2025 across four trades, generating gross proceeds of $524,457.40 in aggregate as reported. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 representations.
Jeanne L. Linnenbringer, Chief Operations Officer of CNO Financial Group (CNO), exercised stock options and sold common stock under a 10b5-1 plan. On 08/13/2025 she exercised 4,420 stock options with a $21.06 exercise price, acquiring 4,420 shares. Those shares and additional holdings were sold under a Rule 10b5-1 trading plan adopted May 5, 2025, with reported sales on 08/13/2025, 08/14/2025 and 08/15/2025 at weighted average prices of about $37.96, $37.9794 and $37.8495 respectively. Reported beneficial ownership fell from 45,583 shares after the option exercise to 30,844 shares after the sales. The filing notes vesting of the options (half vested 02/23/2019 and half 02/23/2020).
Gary C. Bhojwani, Chief Executive Officer and Director of CNO Financial Group, Inc. (CNO), reported multiple gifts of company common stock executed on 08/12/2025. The filing shows disposals by gift: 3,092 shares from personal holdings (reported at $0 per share), 5,904 shares from the Gary C. Bhojwani Revocable Trust (reported at $0), and a further 195,926 shares disposed (listed as a disposal). After the reported transactions, the filing records 698,331 shares beneficially owned following the first disposal, held indirectly. The form is signed by an attorney-in-fact on 08/14/2025. All transactions are labeled as gifts in the explanation.
Form 144 notice for proposed sale of CNO Financial Group, Inc. securities. The filing shows an intended sale of 4,862 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $184,655.84 and 96,931,934 shares outstanding. The approximate date of sale is listed as 08/14/2025 on the NYSE.
The filer reports acquisition details: 1,478 performance shares acquired 02/15/2024 and 3,384 restricted shares acquired 08/09/2024, both from the issuer. The filing also discloses sales during the past three months by Jeanne Linnenbringer totaling 6,420 common shares sold on 08/13/2025 with gross proceeds of $167,782.76 and $75,919.80.
Certain filer and issuer identifying fields (CIK, issuer name, contact details) are not populated in the provided text.